Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bioinformatics -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (35)	9/7/2001 12:31:38 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 80

No down round there......... Locus received a significant increase in valuation from our last financing, which we believe is a strong show of confidence in the current difficult financing environment. We appreciate the support from our investors, and look forward to working with them in continuing to build Locus Discovery,'' commented Nicholas Landekic, President and Chief Executive Officer of Locus Discovery. It's perhaps unfair to assume that these guys didn't get the job done in previous lives, but......... Nicholas Landekic is President, Chief Executive Officer and a member of the Locus Discovery Board of Directors. Mr. Landekic joined Locus from Guilford Pharmaceuticals Inc. of Baltimore, MD, where he served as Senior Vice President of Corporate Development and Communications. Prior to his experience at Guilford, Mr. Landekic worked for Cephalon Inc. as Senior Director of Business Development; for Bristol-Myers Squibb in strategic marketing; and for Johnson & Johnson Corporation in finance and business development positions. He holds a Master's in Business Administration from the State University of New York at Albany as well as a B.S. and M.S. in Biology. William R. Moore, Jr., Ph.D. is Vice President Research & Development and Chief Scientific Officer. Dr. Moore joined Locus after serving as Vice President, Target Discovery, for Axys Pharmaceuticals Inc., where he headed the company's oncology genomics research in La Jolla, CA. Previously, he was Senior Scientific Director at Axys in South San Francisco, and served on six Joint Research Committee collaborations that focused on the preclinical development of small molecule therapeutics. Prior to his experience at Axys, Dr. Moore held various research positions at Marion-Merrell-Dow. He holds a Ph.D. in Chemistry from Brown University and a B.S. in Chemistry from the University of Massachusetts.